Active EST trials
| Intervention . | Clinical trial . | Location . | Phase . |
|---|---|---|---|
| Tabelecleucel | NCT04554914 | Emory University Washington University | 2 |
| Tabelecleucel | NCT03394365, NCT03392142 | Multiple locations (sponsor Atara Biotherapeutics) | 3 |
| CD30 CAR EBVSTs (allogeneic, autologous) | NCT04288726, NCT01192464 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| EBVST cells with nivolumab | NCT02973113 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| Allogeneic LMP1/LMP2-specific cytotoxic T cells and rituximab | NCT02900976 | Multiple locations (sponsor COG) | 2 |
| Third-party LMP-, BARF1-, and EBNA1-specific CTLs | NCT02287311 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| LMP1/2 CTLs | NCT01956084 | Children’s National Medical Center | 1 |
| ESTs | NCT01555892 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| Biologically/genetically modified T cells (19-28z CAR EBV CTLs) | NCT01430390 | MSKCC | 1 |
| CD19 ESTs | NCT00709033 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| TGF-β–resistant LMP-specific CTLs | NCT00368082 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| Intervention . | Clinical trial . | Location . | Phase . |
|---|---|---|---|
| Tabelecleucel | NCT04554914 | Emory University Washington University | 2 |
| Tabelecleucel | NCT03394365, NCT03392142 | Multiple locations (sponsor Atara Biotherapeutics) | 3 |
| CD30 CAR EBVSTs (allogeneic, autologous) | NCT04288726, NCT01192464 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| EBVST cells with nivolumab | NCT02973113 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| Allogeneic LMP1/LMP2-specific cytotoxic T cells and rituximab | NCT02900976 | Multiple locations (sponsor COG) | 2 |
| Third-party LMP-, BARF1-, and EBNA1-specific CTLs | NCT02287311 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| LMP1/2 CTLs | NCT01956084 | Children’s National Medical Center | 1 |
| ESTs | NCT01555892 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| Biologically/genetically modified T cells (19-28z CAR EBV CTLs) | NCT01430390 | MSKCC | 1 |
| CD19 ESTs | NCT00709033 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
| TGF-β–resistant LMP-specific CTLs | NCT00368082 | Houston Methodist Hospital Texas Children’s Hospital | 1 |
Shown are current active EST trials registered on clinicaltrials.gov at time of submission.
CAR, chimeric antigen receptor; CTL, cytotoxic T lymphocyte; EBVST, EBV-specific T cells; TGF, transforming growth factor.